Какова цена за Opus Genetics, Inc. (IRD)

Цена за Opus Genetics, Inc. (IRD) Это $3.70

Какова рыночная капитализация для Opus Genetics, Inc. (IRD)

Рыночная капитализация для Opus Genetics, Inc. (IRD) Это $305.87M

Opus Genetics, Inc. (IRD) История Цен

Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.

Год	Результативность
2026 (TTM)	51.09%
2025	96.16%
2024	0.00%

Год

Результативность

2026 (TTM)

51.09%

2025

96.16%

2024

0.00%

Компания	Цена акций	Изменение 1г%	Страна
Vertex Pharmaceuticals Incorporated VRTX.US	$548.15	40.18%	US
Argenx SE ARGX.US	$1.03K	44.14%	NL
Moderna, Inc. MRNA.US	$153.87	538.73%	US
CSL Limited CSL.AX	$121.37	-11.93%	AU
Lonza Group AG LONN.SW	$748.60	4.92%	CH

Компания

Цена акций

Изменение 1г%

Страна